Acyl-CoA:1,2-diacylglycerol acyltransferase Inhibitors
2 drugsAbout Acyl-CoA:1,2-diacylglycerol acyltransferase
Acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT) catalyzes the final step in triglyceride synthesis, a key process for energy storage and lipid metabolism. By regulating triglyceride production, DGAT plays a crucial role in lipid homeostasis.
DGAT is a relevant target for drug development due to its role in triglyceride production, though there is currently no genetic evidence directly linking it to specific diseases. Inhibiting DGAT can potentially modulate lipid levels, making it of interest for various therapeutic areas.
Two FDA-approved drugs, LOVAZA and OMEGA-3-ACID ETHYL ESTERS, target DGAT as small molecules. These drugs are marketed by Apotex and WAYLIS THERAP for other indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Breast Atypical Hyperplasia with only 1 trials.
- phase1 represents biological uncertainty with 38% completion.
Top Acyl-CoA:1,2-diacylglycerol acyltransferase Drugs
Apotex and WAYLIS THERAP are the only two companies with approved drugs targeting DGAT.
Low market concentration suggests an opportunity for new entrants, but also highlights potential challenges in demonstrating clinical efficacy.
Acyl-CoA:1,2-diacylglycerol acyltransferase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Acyl-CoA:1,2-diacylglycerol acyltransferase, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
Acyl-CoA:1,2-diacylglycerol acyltransferase Clinical Trials 45 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 17 | 4 | 13 | 0 | 24% |
| Phase 2 | 11 | 7 | 2 | 2 | 78% |
| Phase 3 | 8 | 6 | 2 | 0 | 75% |
| Phase 4 | 9 | 7 | 2 | 0 | 78% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Acyl-CoA:1,2-diacylglycerol acyltransferase Drug Approval Timeline (2004 - 2004)
The first DGAT-targeting drug was approved in 2004, and the most recent in 2014, spanning 11 years.
The approval timeline suggests a potentially saturated market, requiring strong differentiation for new drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 28 clinical trials targeting Acyl-CoA:1,2-diacylglycerol acyltransferase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities